Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aquestive Therapeutics, Inc.

NASDAQ: AQST · Life Sciences · 12 alerts · CIK 1398733

Share price
$3.76Close, Nov 16
Market cap
$473M
Shares outstanding
125.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aquestive Therapeutics, Inc. filings on SEC EDGAR ↗

6:37 AM ET 8-K
Investor Presentation

Aquestive Therapeutics Investor Presentation

Aquestive Therapeutics filed an investor presentation for the Jefferies Global Healthcare Conference on November 16, 2026. The presentation provides updates on the regulatory status of Anaphylm (epinephrine) sublingual film, including the March 16, 2027 PDUFA goal date, and the commercial launch strategy for the product if approved.

4:21 PM ET 8-K
Investor Presentation

Aquestive Therapeutics Investor Presentation

Aquestive Therapeutics filed a corporate investor presentation for November 2026 to be used in meetings with institutional investors and analysts. The presentation provides updates on the regulatory status of Anaphylm (sublingual epinephrine) following its NDA resubmission, which has a PDUFA goal date of March 16, 2027, and the development of its AdrenaVerse pipeline including AQST-108.

8:00 AM ET 8-K
Investor Presentation

Aquestive Therapeutics Investor Presentation

Aquestive Therapeutics filed a corporate investor presentation dated September 23, 2026, to be used in meetings with institutional investors and analysts. The presentation provides updates on the company's AdrenaVerse pipeline, including the regulatory status of Anaphylm (epinephrine) sublingual film following its NDA resubmission to the FDA and the development of AQST-108 for dermatologic indications.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.